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Sixty patients with recurrent Inducible sustained ventricu-
lar techycardia wee prospectively treated with adolol (40
or 80
nag/day).
Old myocardial infarction was present in 43
patients and dilated cardiomyopathy In 12 . In group I (n =
36), aadutol was given alone, whereas in group It in = 241,
previously ineffective treatment with aniodareee was con-
tlnted In combination with nudolol . Left ventricular ejrc-
Had fraction was higher in patients In group 1(0 .40 t 0
.12)
titan In group 11(0.30 d: 0 .10, p < 0.01) patients. Elects.
physiologic study gas repeated after short-term treatment
with naddal, which was continued regardless of the results
of this test, according to the scheme of the parallel ap.
1
	
.
Recurrence ofspontaneous tachyardia or sudden death
occurred in 21 patients alter 10 t 9 .2 months; sustalv:d
tachyardis was inducible in 19 on ndolul therapy. The
remasing 39 patients (of whom 21 had iducible tachynr-
dia while taking the drug) have had no recurrence of
taehycnrdia after 27.8 t 93 months of follow-up study .
Serial drug testing with electrophysiologic studies is often
proposed to assess the efficacy of antiarrhythmic therapy in
patients with serious ventricular arrhythmias. Controversy
concerning the value of these tests has been recently re-
ported ; Brugada and Wellens (1) proposed using a parallel
approach to assess the validity of a test before considering
the classic serial approach .
In almost all studies, the tested drugs were
class I
antiarrhythmic drugs and, more recently, amiodaone (2-8)
.
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Sensitivity, spec-city and predictive value of a positive and
negative test were 90.5%, 46%, 47 .5% and 90% . respec-
tively. The results dyer between group I nod group 11
patients, the alter having a high percent of false positive
responses
. ThisdiCeaceIavenwaste obvious with
1spart
to left
ventricular
ejection f1ract on: the predictive van of
∎ positive test was 86% when ejection traction was >0.46
and 39% when h was <0
.40, A long (>4M ms) cycle length
of the induced
ventricular
tochyeardia seems waste predio
live of recurrence or madden death (11 of 14 comparedwith
9 of 26 faster tachycardlm, p < 0.01).
Electropbysedagic studies me suit" for evr miles of
the atiarrbythmk
effect
of a Ma-blacker a the veutelo-
nIne tachycardtasubduate, with the se restrictions restrictions 0 for
other drugs in patients with tow left ventricular ejection
fraction. A heta.hlocker should be included is serial drag
testing in patients with sustained vedtelcular lacbycardla.
(J Am Col Cmilef 199P1fr413-7)
4 1 3
No consistent data on the value of these tests in the patient
on betaadrenergic blocking therapy are yet available. We
have prospectively used beta-blocking agents alone or with
other antiarrhythmic agents to control
sustained ventricular
arrhythmias for several years. This report presents our
experience with electrophysiologic studies using a parallel
approach in these patients,
Methods
Study pnlients
. A cooperative prospective study involv-
ing four centers included 60 patients with sustained
recurrent
monomorphic ventricular tachycardia who consented to the
study protocol, which was approved by the regional Ethics
Cormittee. All patients had an electrophysiologic study
before the onset of beta-blocking therapy, and sustained
0735-1097r5a'55.50
414
	
LECLERCQ ET AL .
NADOLGL FOR VENTRICULAR TAC14YCARDIA
Table l . Predictive Value of Electrophysiologic Study in 60 Patients
Positive
Negative
Group No.
Tell
Tesl
1 36 20 16
11 24 20 4
monomorphic ventricular tachycardia was inducible with the
study protocol. There were 55 men and 5 women, 51 ± I I
years of age (mean ± SD) with coronary artery disease in 43,
dilated cardiomyopathy in 12, primary right ventricular
disease in 3, aortic valve disease in I and an apparently
normal heart in 1 . The pattern of the clinical ventricular
tachycardia was right bundle branch block in 47 patients, left
bundle branch block in 12 and undetermined in I ; the
tachycardia cycle length was 296 ± 17 ms . Spontaneous
tachycardia occurred during exercise in only 6 patients ; its
clinical tolerance was acceptable in 51 patients, whereas 5
experienced syncope and 4 had cardiac arrest. Cardiover-
sion terminated the tachycardia in 53 of the 60 patients .
Patients were divided in two groups . In the 36 group I
patients, beta-blocking therapy (nadolol) was given alone
and all other pre"iously used antiarrhythmic drugs were
stopped . In the 24 group 11 patients, nadolol was combined
with amiodarone, which had been used for >6 months and
was continued at the same dosage during the study . In this
latter group, the initial electrophysiologic study with the
patient on amiodarone therapy induced sustained ventricular
tachycardia. Patients in groups I and 11 did not differ in age,
gender ratio or underlying heart disease, but group 11 pa-
tients had had more attacks of ventricular tachycardia (6 .4 ±
5 .1 versus 3.4 ± 3 .2, p < 0.05) and had a lower isotopic left
ventricular ejection fraction (0.301 ± 0.096 versus 0.401 ±
0.125, p < 0
.01).
Electrophysiologic study
. In the following order, our pro-
tocol included 1) twice threshold ventricular pacing with
progressive reduction in the cycle length to 260 ms ; 2) single
extrastimulation up to the refractory period then double
extrastimulation up to the refractory period on a basic
ventricular paced cycle length of 600 ms; and 3) single then
double extrastimulation on a paced cycle length of 400 ms .
The right ventricular apex was used as a first site, and in the
case of a negative response, the right ventricular outflow
tract as a second site . No catecholamine infusion was used,
Induction of sustained (>30 s) monomorphic ventricular
tachycardia was called a positive electrophysiologic study
result, whereas induction of nonsustained monomorphic or
polymorphic ventricular tachycardia as well as noninducibil-
ity of any arrhythmia were called a negative response .
Treatment. Beta-blocking therapy consisted of nadolol,
80 mg/day in patients with >70 kg body weight and left
ventricular ejection fraction >0 .30, or 40 mg/day in patients
True
False True False
Positive
Positive Negative
Negative
12
7
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Group 1: sensitivity = 86% : specificity = 64%: predictive value of a positive test = 60s0o; predictive value c: a negative test = 87.5%. Group 11:
sensitivity = Imo ; specificity = 24%; predictive value
of
a positive test = 35% ; predictive value of a negative test = 100%.
<70 kg or with an ejection fraction <0 .30. The dose of
nadolol was not statistically different between groups I and
11(67 ± 19 versus 60 ± 22 mg/day, respectively, p = NS) . In
patients with an ejection fraction <0 .40, beta-blocking ther-
apy started with acebutolol or celiprolol, drugs having an
intrinsic sye 7athomimetic activity ; nadolol w.s substituted
for acebutolol or celiprolol after 3 to 5 days . Electrophysio-
logic study was performed after 5 to 7 days of nadolol
therapy, and the patients were discharged on this drug
regardless of the results of the electrophysiologic study,
according to the plan of the parallel approach. Clinical
response was judged as I) spontaneous recurrence of sus-
tained ventricular tachycardia necessitating a therapeutic
intervention, or 2) death . End points of the study were both
sudden death (<I h after initial symptom) and spontaneous
sustained ventricular tachycardia .
Statistical analysis. The chi-square test or Student's r test
was used to compare the two groups of patients . Actuarial
incidence of tachycardia recurrence was evaluated by Kap-
lan-Meier curves and compared by the log-rank test. Prob-
ability (p) values <0.05 were considered significant.
Results
Results of the electrophysiologic study. In group I, elec-
trophysiologic study results were negative in 16 patients
(44%) and remained positive in 20 (56%), whereas in group Il
patients, they were negative in only 4 (17%) and positive in
20 (83%) . This difference between the two groups is signifi-
cant (p < 0 .02), which may mainly be due to the difference in
left ventricular ejection fraction because a retrospective
subgroup analysis of the results shows an even more signif-
icant difference according to this variable ; the electraphysi-
ologic study results were negative in 13 (65%) of 20 patients
with an ejection fraction >0 .40 compared with 7 (17 .5%) of
40 patients with an ejection fraction of <0 .40 (p < 0 .001) .
Predictive value of the eleetophysiologic study. Table I
indicates the Tong-term outcome on nadolol therapy assessed
by the electrophysiologic study ill the two groups . The
follow-up period in the 39 patients free of recurrence of
sustained ventricular tachycardia or sudden death is 27 .8
9
.3 months, longer than the delay of recurrence of ventric-
ular tachycardia or sudden death in the remaining 21 patients
(10 ± 9.2 months, p < 0 .001) .
For the entire series, the sensitivity of the electrophysi-
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Figure 1. Kaplan-Meier survival curves for patients free of tachy-
cardia recurrence and sudden death, according to the results of the
electrophyslologic study in 60 patients e; nadolol therapy . Numbers
represent patients available for comparison at each time interval
.
The difference between patients with inducible and noninducible
tachyarrhythmia is significant (p < 0.01)
.
olegic study was 90.5%, its specificity was 46%, the positive
predictive value of a positive test was 47 .5% and that of a
negative test was 90%. However, these values differed
between the two groups (Table I), with a higher number of
false positive resuits in group 11 patients (13 of 24 patients
compared with 8 of 36 in
group I, p < 0.01). Again, this
difference between groups may mainly be due to differences
in left ventricular function rather than to the treatment
because all except one false positive result appeared in
patients with a left ventricular ejection fraction <0 .40 (Table
2).
The actuarial incidence of recurrence of ventricular
tachycardia (Fig . I) was statistically higher in patients with
inducible tachycardia (p < 0 .01) .
Role of the ventricular tachycardia rate . The value of the
induced ventricular rate seems to be related to the clinical
outcome (Fig. 2) . Among 14 patients with an induced tachy-
cardia cycle length >400 ms during nadolol therapy, 9 had a
recurrence of tachycardia and 2 died suddenly, whereas only
9 recurrences and no sudden deaths occurred in the 26
Table 2 . Role of Left Venricular Ejection Fraction in 60 Patients
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Figure 2. Incidence of ventricular tachycardia (VT) recurrence or
sudden death (dated tea), according to the cycle length of the
induced ventricular tachycardia .
patients with an induced tachycardia cycle length <400 ms at
electrophysiologic study (p < 0 .01) . Conversely, a slower
induced tachycardia was not related to the clinical outcome .
Among 14 patients with an increase in tachycardia cycle
length of >50
ms, 7 had a tachycardia recurrence, and
among 26 patients with unchanged tachycardia cycle length,
12 had a tachycardia recurrence (p = NS).
Tolerance to sadold . Side effects were relatively rare in
this prospective study . Aggravation of hear failure occurred
in six patients, leading to discontinuation of nadold in four,
which was also necessary in one patient with intolerable
fatigue . An aerial demand (AAl) or dual chamber (DDD)
pacemaker had to be implanted in nine patients (three in
group I, six in group II) because of severe sinus bradycardia .
Nine patients died during the follow-up: four of heart failure
(in two after nadolol treatment was discontinued) and five
suddenly (two within 2 months after stopping nadolol ther-
apy and one 4 months after stopping antiodarone because of
hyperthyroidism)
.
Discussion
Beta-blockers and ventricular tachycardia
.
Very few re-
ports on electrophysiologic studies of patients with ventric-
ular tachycardia include patients treated with a beta-
blocking agent (9,10) and these reports described only small
series
. More recently, some larger series (11,12) included
patients treated with sotalol, a beta-blocker that also has a
O ro,eaaninn
∎IdandrMr
F1 vrne'eiss*
Left ventricular ejection fraction ILVEF) >0 .40 : sensitivity = 75%: specificity = 92%; predictive vakw ore positive test 86%; predictive value ofa massive
test =85% . LeovenldculNejectiaefroction<0 .4nsensitivity=100%;specificity=26%
:predictivevdueofapoeiliveteet 39%
;predictivevalueofanegatiee
less = 100%.
LVEF No.
Positive
Test
Negative
Test
True
Positive
Use
Potilive
True
Negative
False
Neptve
>0.40
20
7 13 6 1 II 2
<0 .40 40 33 7 13 20 7
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direct class III antiarrhythmic effect, but their favorable
results cannot be extrapolated to the usual beta-blocking
agents. This fact contrasts with the well recognized impor-
tance of an increased sympathetic tone in the genesis of
sudden death from ventricular tachyarrhythmias (13,14) and
with the preventive effect of beta-blockin,^ agents on sudden
death after myocardial infarction (15,16) . This effect is
correlated with the obtained sinus bradycardia (17) . The
mechanisms of sudden death from ventricular tachyarrhyth-
mias, especially in chronic coronary artery disease, include
an electrophysiologic substrate of ventricular tachycardia or
fibrillation and triggering factors, namely, ventricular prema-
ture beats and increased sympathetic tone (18)
.
If such is the
case, it could be hypothesized that beta-blocking agents may
have a favorable effect on the ventricular tachycardia sub-
strate in addition to their effects on triggering factors .
Effects of nudool on the elecrophysiologie substrate. Our
study seems to confirm this hypothesis because 46% of
patients treated with nadolol alone had a negative electro-
physiologic study result, which was a possibility mentioned
in the initial studies (2,3)
. However, in group II patients
previously treated with amiodarone, only a small proportion
(17%) responded to nadolol on the basis of the electrophys-
iologic study . It is important to discriminate between a true
antiarrhythmic effect on the electrophysiologic properties of
the ventricular tachycardia substrate and an artifact due to
an inadequate protocol or lack of reproducibility of the
electrophysiologic study. It has been demonstrated that
induction of polymorphic ventricular tachycardia (19) or
ventricular fibrillation (20) has a low clinical relevance
compared with induction of sustained monomorphic ventric-
ular tachycardia (21).
Similarly, using three extrastimuli (22)
or multiple sites of stimulation (23) increases the sensitivity
of the study, but decreases its specificity dramatically, and
the majority of the admitted "standardized" protocols of
electrophysiologic study (24) include only two extrastimuli
and a maximum of two sites
. Our protocol was in accordance
with these recommendations
.
Recently, some investigators (25,26) reported results sug-
gesting that modifications of the ventricular tachycardia
substrate are sufficient to obtain a significant degree of
clinical efficacy in the prevention of spontaneous ventricular
tachycardia or sudden death; obtaining a slowed induced
ventricular tachycardia may be sufficient in some cases .
However, other studies (27,28) showed that slowing intra-
ventricular conduction (assessed by paced QRS duration) is
more marked in nomesponders than in responders . In our
study, considering a slowed ventricular tachycardia as a
negative response to electrophysiologic study does not
change the number of false positive responses
.
Determinants of the response to a beta
•blocker. If the
electrophysiologic study protocol is not a source of error, it
could be
concluded that the percent of responders is lower in
the patients receiving combined amiodarone and nadolol
JACC Val. I6 . No. 2
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therapy and even more different between patients with
conserved versus severely impaired left ventricular function.
In our study, these findings were established by retrospec-
tive analysis and are thus subject to criticism ; however,
similar data have been reported (29-31) with other antiar-
rhythmic drugs and the data appear nonspecific for beta-
blocking therapy
. The reasons for this higher rate of re-
sponders among patients with good left ventricular function
are unknown
. The degree of left ventricular dysfunction
seems to be a determinant not only of the percent of
responders to electrophysiologic study, but also of clinical
outcome . Discrepancies between electrophysiologic study
results and outcome were mainly due to a high rate of false
positive results, which were observed almost exclusively in
patients with depressed left ventricular function. In this
case, false positive responses could be due to a predominant
effect of antiarrhythmic drugs on the other factors leading to
spontaneous ventricular tachycardia (that is, triggcring fac-
tors or sympathetic tone, or both)
.
Beta-blocking therapy is the only effective treatment for
reducing sympathetic drive and it is not surprising to observe
a high percent of false positive responses at electrophysio-
logic study (ventricular tachycardia substrate is still present,
but no clinical ventricular tachycardia will occur because of
the effect of the drug on the main predisposing factor) . This
difference between effects of beta-blocking agents on ven-
tricular tachycardia substrate and triggering factors has been
observed experimentally (32) .
Clinical implications . Beta-blocking agents may have a
direct effect on the ventricular tachycardia substrate in
addition to an effect on the factors predisposing to clinical
ventricular tachycardia. Results of electrophysiologic testing
are not different from those obtained with other drugs, like
amiodarone
; there is a good clinical correlation in patients
with preserved left ventricular function and a higher propor-
tion of false positive results in patients with left ventricular
dysfunction. There is no reason to consider beta-blocking
agents differently from other antiarrhythmic drugs or to
minimize their usefulness in the treatment of ventricular
tachyarrhythmias .
We thank Isabelle Detljoy, MD for her help in the preparation of this report
and Annie Gouverneur for secretarial pssistaooe .
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